Clinical TrialHighlighted
MHID-0587967PMID: 319380042019Biology of Sport
Dejan Javorac, Valdemar Stajer, Laszlo Ratgeber, Jozsef Betlehem, Sergej Ostojic
In this randomized, double-blind, placebo-controlled, crossover pilot trial, we evaluated the effects of 7-day H2 inhalation on exercise performance outcomes and serum hormonal and inflammation profiles in a cohort of young men and women. All participants (age 22.9 ± 1.5 years; body mass index 23.4 ± 2.5 kg m-2; 10 women and 10 men) were allocated to receive either gaseous hydrogen (4%) or placebo
Clinical TrialHighlighted
MHID-9688108PMID: 309827482019Clinics and Research in Hepatology and Gastroenterology
Darinka Korovljev, Valdemar Stajer, Jelena Ostojic, Tyler W. LeBaron, Sergej M Ostojic
Background and aims: While non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide, its treatment remains elusive. Since metabolic impairment plays a major role in NAFLD pathogenesis, any pharmaceuticals, such as molecular hydrogen (H2), that advance lipid and glucose metabolism could be appropriate to tackle this complex condition. The aim of this stu
Clinical Trial
MHID-9868845PMID: 285605192018Irish Journal of Medical Science
D. Korovljev, T. Trivic, P. Drid, S. M. Ostojic
Background: Molecular hydrogen (H2) effectively treats obesity-related disorders in animal models, yet no studies have investigated the effectiveness and safety of H2 for improving biomarkers of obesity in humans.
Aim: In this double blind, placebo-controlled, crossover pilot trial, we evaluated the effects of H2 intervention on body composition, hormonal status, and mitochondrial function in ten
Animal StudyHighlighted
MHID-6423123PMID: 298670312018Toxins
Weijiang Zheng, Xu Ji, Qing Zhang, Wenchao Du, Quanwei Wei, Wen Yao
The objective of the current experiment was to evaluate whether hydrogen-rich water (HRW) or lactulose (LAC) could protect against the adverse effects of Fusarium mycotoxins-contaminated diet on the growth performance and antioxidant status in weaning piglets. A total of 24 individually housed female piglets were randomly assigned to receive four treatments for 25 days (six pigs/treatment): uncont
Animal StudyHighlighted
MHID-6379034PMID: 284624512017Neurochemical Research
Yusuke Yoshii, Taikai Inoue, Yuya Uemura, Yusaku Iwasaki, Toshihiko Yada, Yusaku Nakabeppu, et al.
Molecular hydrogen (H2), as a new medical gas, has protective effects in neurological disorders including Parkinson’s disease (PD). In our previous report, the neuroprotective effect of drinking water with saturated H2 (H2 water) in PD mice might be due to stomach–brain interaction via release of gastric hormone, ghrelin. In the present study, we assessed the effect of H2-induced ghrelin more prec
Literature ReviewAnimal StudyIn VitroHighlighted
MHID-45285932014European Journal of Neurodegenerative Diseases
Mami Noda, M. Ito, I. Ohsawa, K. Ohno
A new medical gas, molecular hydrogen (H2), has been reported to be effective for a variety of disorders and clinical trials have shown promising results. Though the precise mechanism is still unknown, it is obvious that H2 has multiple effects. The first prominent effect of H2 was as antioxidant or reactive oxygen species (ROS)-scavenger, though it blocks only hydroxyl radicals (•OH), which are t
Animal StudyHighlighted
MHID-1568601PMID: 242536162013Scientific Reports
Akio Matsumoto, Megumi Yamafuji, Tomoko Tachibana, Yusaku Nakabeppu, Mami Noda, Haruaki Nakaya
The therapeutic potential of molecular hydrogen (H2) is emerging in a number of human diseases and in their animal models, including in particular Parkinson’s disease (PD). H2 supplementation of drinking water has been shown to exert disease-modifying effects in PD patients and neuroprotective effects in experimental PD model mice. However, H2 supplementation does not result in detectable changes
